Kexing Biopharm (688136.SH) terminates clinical trial of recombinant human interferon 2b nasal spray.
Kexing Pharmaceutical (688136.SH) announced that the company's research and development of interferon 2b spray is in the clinical research stage.
Kexing Biopharm (688136.SH) announced that the company's development of interferon 2b nasal spray is in the clinical research stage. Recently, after careful consideration of the drug's future development risks, the company has decided to terminate the clinical trials of this project.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
